摘要
目的探讨唑来膦酸钠治疗糖尿病性骨质疏松症(DOP)的临床效果。方法选取2011年1月—2012年5月在我院确诊的DOP患者68例,将其随机分为治疗组(n=34)和对照组(n=34)。治疗组给予钙尔奇+阿法D3+唑来膦酸钠治疗,对照组给予钙尔奇+阿法D3治疗,疗程均为1年。治疗2周后评价两组患者疼痛症状改善情况;测定治疗前和治疗1年后两组患者髋骨和腰椎骨密度(BMD),血钙、磷和碱性磷酸酶(AKP)水平;治疗过程中观察药物不良反应情况。结果治疗2周后对照组疼痛症状改善有效率为53.3%,低于治疗组的90.3%(P<0.05);治疗后治疗组腰椎和髋骨BMD均高于对照组,AKP水平低于对照组(P<0.05)。治疗组在治疗过程中未出现严重不良反应。结论唑来膦酸钠能缓解DOP患者骨痛,提高骨密度。
Objective To discuss the effect of Zoledronic acid in the treatment of diabetic osteoporosis （DOP）. Methods 68 patients with DOP were chosen from January 2011 to May 2012, they were randomly divided into treatment group （n =34） and control group （n --34）. The treatment group received Cahrate ＋ Alpha D3 ＋ Zoledronic acid, and the control group received Caltrate ＋ Alpha DB, both treated for 1 year. The status of pain and symptom improvement in the two groups were evaluated after 2 weeks; The bone mineral density （BMD） of hip and lumbar spine, calcium, phosphorus and alkaline phos- phatase （AKP） in the two groups were measured before treatment and after 1 year; The adverse reactions of drugs were observed during treatment. Results After 2 weeks＇ treatment, the efficacy of pain and symptom improvement in control group was 53.3% , lower than that of treatment group of 90. 3% （P 〈0. 05） ; After one year＇treatment, BMD of lumbar spine and hip of treatment group were higher, AKP levels was lower than that of control group （P 〈 0. 05）. No serious adverse reaction of drugs occurred in treatment group during treatment. Conclusion Zoledronic acid can significantly relieve pain and improve BMD in patient with DOP.
出处
《实用心脑肺血管病杂志》
2013年第12期40-42,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
唑来膦酸钠
骨质疏松
糖尿病
2型
治疗结果
Zoledronic acid
Osteoporosis
Diabetes mellitus, type 2
Treatment outcome
